UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State or Other Juris ...

flexion Transformative Medicine... Where It Matters Q4 2020 Commercial Metrics March 10, 2021 Overview 2 • ZILRETTA® net sales of $26.3 million in Q4 2020 • Net sales for full-year 2020 totaled $85.6 million • 4,248 accounts had purchased ZILRETTA as of December 31, 2020; up from 4,072 as of September 30, 2020 • 3,321 accounts had re-ordered ZILRETTA (78% of accounts that had purchased), as of December 31, 2020; up from 3,153 accounts that had re-ordered ZILRETTA (77% of accounts that had purchased) as of S ...

Flexion Therapeutics, Inc. (FLXN) Q4 2020 Earnings Conference Call March 10, 2021 4:30 PM ET Company Participants Scott Young - Vice President of Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Melissa Layman - Chief Commercial Officer David Arkowitz - Chief Financial Officer Conference Call Participants Randall Stanicky - RBC Capital Markets Elliot Wilbur - Raymond James Gary Nachman - BMO Capital Markets Serge Belanger - Needham & Company Patrick Trucchio - H.C. Wai ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdictio ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2020 Earnings Conference Call October 29, 2020 8:30 AM ET Company Participants Susan Mesco - Head of Investor Relations David Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants Randall Stanicky - RBC Capital Markets David Amsellem - Piper Sandler David Steinberg - Jefferies Balaji Prasad - Barclays Greg Fraser - Truist Securities Gary Nachman - BMO Serge Belanger - Needham & Company Ami Fadia - SVB Leer ...